Breaking News

U.S. DoD Awards Grant to SiteOne Therapeutics

The support will help the research and development of a molecule to treat acute and chronic pain

SiteOne Therapeutics has been awarded a grant by U.S. Dept. of Defense in the effort to develop the company’s proprietary, highly selective small molecule NaV1.7 inhibitors for the treatment of acute and chronic pain.    SiteOne Therapeutics co-founder and vice president of research, John Mulcahy, said, “The validation and confidence of officials of the U.S. Department of Defense is exceptionally welcome.  There is a critical need for non-opioid therapeutics that treat acute ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters